[FDG-PET in localization of cancers of unknown primary origin].
FDG-PET can be successful in localizing the primary cancer when a metastasis is discovered but no primary tumor can be identified (cancer of unknown primary, or CUP) by physical examination, laboratory testing (for tumor markers, for example) or conventional imaging. The greatest number of PET studies in CUP concern secondary lesions in cervical lymph nodes, and PET is an established clinical use (highest ranking, 1A) according to the 3rd German Consensus Conference and an "option" in the French Standards, Options, and Recommendations. Success rates range from 30% to 50% in most studies using PET; a higher rate was reported recently with PET/CT. FDG-PET should be performed sufficiently early in cases of neurological paraneoplastic syndrome, because established lesions become irreversible. Identification of the antibody present helps to specify the organ and FDG-PET can then localize the lesion; together these techniques make it possible to perform curative surgery even when the primary tumor is not visible. The success rate is somewhat lower than in cases of metastasis, around 35%. The clinical utility of PET in other paraneoplastic syndromes has not yet been sufficiently studied, but these conditions are rare. It is precisely in cases with a kind of 'orphan' indication that FDG PET should be considered, as an effective "problem solver".
Talbot
Jean-Noël
JN
Service de Médecine Nucléaire, AP-HP Hôpital Tenon, Université Pierre et Marie Curie, Paris. jean-noel.talbot@tnn.ap-hop-paris.fr
Kerrou
Khaldoun
K
Gutman
Fabrice
F
Périé
Sophie
S
Grahek
Dany
D
Roulet
Etienne
E
Saint Guily
Jean Lacau
JL
Montravers
Françoise
F
D019788:Fluorodeoxyglucose F18; D006801:Humans; D009382:Neoplasms, Unknown Primary / Q000000981:diagnostic imaging*; D020361:Paraneoplastic Syndromes, Nervous System / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18